Skip to main content
. 2020 Apr 1;19(6):3859–3870. doi: 10.3892/ol.2020.11502

Figure 6.

Figure 6.

Kaplan-Meier survival analyses among T790M-positive NSCLC. (A) Kaplan-Meier estimates of progression-free survival (15.6 months vs. 3.6 months) of osimertinib treatment between patients with or without concomitant alterations beyond EGFR; (B) Kaplan-Meier estimates of overall survival (NR vs. 32.8 months) of osimertinib treatment between patients with or without concomitant alterations beyond EGFR. NR, not reached; EGFR, epidermal growth factor receptor; HR, hazard ratio.